⌕
Dexcom · DXCM · Nasdaq
Tenet 55 · Mixed
Compare
$82.04+0.53%At closeTenet 55 · Mixed
$82.04+0.43 (+0.53%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$81.98−0.06 (−0.07%)
After hours: Nov 17, 2026, 6:23 PM ET

Dexcom (DXCM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~17.5%/yr (FY21→FY25), net margin 17.9%, and free cash flow (~$1.1B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲15.6%
4,662.0
FY21→FY25CAGR +17.5%/yr
Net income ($M)▲45.1%
836.3
FY21→FY25CAGR +40.1%/yr
Free cash flow ($M)▲70.8%
1,077.2
FY21→FY25CAGR +112.0%/yr
Diluted EPS▲47.2%
2.09
buyback-liftedCAGR +40.9%/yr
What the receipts whisper · what a headline number hides
Share count
−5.4%

428.8mn → 405.5mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$363.5M

steady at 7.8% of revenue (+1.3% YoY).

Returns vs FCF
46%

$0.5B returned vs $1.1B of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)4662.0Revenue−1860.1COGS2801.9Gross profit−599.1R&D−1291.0SG&A911.8Op income−75.5Tax & other836.3Net income

18¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~3%FY21FY25

Over this window: gross 68.6% → 60.1%. Net margin 17.9% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
5,104,400.04,662,000.04,033,000.03,622,300.02,909,800.02,448,500.0▲15.6%+17.5%
Cost of revenue
1,867,000.01,860,100.01,594,800.01,333,400.01,026,700.0768,000.0▲16.6%+24.8%
Gross profit
3,237,400.02,801,900.02,438,200.02,288,900.01,883,100.01,680,500.0▲14.9%+13.6%
Research & development
608,100.0599,100.0552,400.0505,800.0484,200.0604,200.0▲8.5%−0.2%
Selling, general & admin
1,405,500.01,291,000.01,285,800.01,185,400.01,007,700.0810,500.0▲0.4%+12.3%
Total operating expenses
2,013,600.01,890,100.01,838,200.01,691,200.01,491,900.01,414,700.0▲2.8%+7.5%
Operating incomefeeds ROC rank
1,223,800.0911,800.0600,000.0597,700.0391,200.0265,800.0▲52.0%+36.1%
Other income, net
38,600.0176,600.0109,000.0112,700.0−400.0−9,000.0——
Pretax income
1,262,400.01,088,400.0709,000.0710,400.0390,800.0256,800.0▲53.5%+43.5%
Income tax
271,400.0252,100.0132,800.0168,900.049,600.039,900.0▲89.8%+58.5%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
991,000.0836,300.0576,200.0541,500.0341,200.0216,900.0▲45.1%+40.1%
Per share
Diluted EPSbuyback-sensitive
2.542.091.421.300.820.53▲47.2%+40.9%
Diluted shares (mn)
383.50405.50412.70425.50427.50428.80▼1.7%−1.4%
Margins
Gross margin45th pct in Healthcare
63.4%60.1%60.5%63.2%64.7%68.6%▼0.4pp−8.5pp
Operating margin
24.0%19.6%14.9%16.5%13.4%10.9%▲4.7pp+8.7pp
Net margin83rd pct in Healthcare
19.4%17.9%14.3%14.9%11.7%8.9%▲3.7pp+9.1pp
† TTM = trailing four quarters through 2026-09-30.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Dexcom's revenue last fiscal year?

Dexcom reported revenue of $4,662.0M in fiscal 2025, up 15.6% from fiscal 2024.

What was Dexcom's net income?

Dexcom reported net income of $836.3M in fiscal 2025, a net margin of 17.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.